Skip to main content

Table 2 Genotype frequencies: MTHFR C677T

From: A retrospective comparative exploratory study on two Methylentetrahydrofolate Reductase (MTHFR) polymorphisms in esophagogastric cancer: the A1298C MTHFR polymorphism is an independent prognostic factor only in neoadjuvantly treated gastric cancer patients

        MTHFR C677T    p
     CC   CT    TT  
All patients   254 (44.6%) 262 (46.0%) 53 (9.3%)  
Status Alive 143 (42.2%) 162 (47.8%) 34 (10%) 0.342
  Dead 111 (48.3%) 100 (43.5%) 19 (8.3%)  
Sex Male 189 (43.9%) 202 (46.9%) 40 (9.3%) 0.775
  Female 65 (47.1%) 60 (43.5%) 13 (9.4%)  
Localization AEG 153 (43.6%) 169 (48.1%) 29 (8.3%) 0.337
UICC 7th edtiion Gastric cancer 99 (46.7%) 90 (42.5%) 23 (10.8%)  
Localization AEG I 63 (44.1%) 68 (47.6%) 12 (8.4%) 0.868
UICC 6th edition AEG II/III + GC 191 (44.8%) 194 (45.5%) 41 (9.6%)  
Laurén Intestinal 137 (42.8%) 151 (47.2%) 32 (10.0%) 0.731
  Non-intestinal 107 (45.7%) 107 (45.7%) 20 (8.5%)  
Grading Low grade 74 (44.6%) 75 (45.2%) 17 (10.2%) 0.89
  High grade 174 (44.1%) 185 (46.8%) 36 (9.1%)  
pT pT0 14 (36.8%) 21 (55.3%) 3 (7.9%) 0.751
  pT1 20 (38.5%) 28 (53.8%) 4 (7.7%)  
  pT2 134 (48.6%) 118 (42.8%) 24 (8.7%)  
  pT3 78 (42.4%) 86 (46.7%) 20 (10.9%)  
  pT4 8 (42.1%) 9 (47.4%) 2 (10.5%)  
pN pN0 109 (45.0%) 115 (47.5%) 18 (7.4%) 0.642
  pN1 93 (46.3%) 88 (43.8%) 20 (10.0%)  
  pN2 31 (41.9%) 33 (44.6%) 10 (13.5%)  
  pN3 12 (42.9%) 15 (53.6%) 1 (3.6%)  
  pNx 9 (37.5%) 11 (45.8%) 4 (16.7%)  
pM pM0 236 (45.0%) 243 (46.3%) 46 (8.8%) 0.292
  pM1 18 (40.9%) 19 (43.2%) 7 (15.9%)  
R R0 213 (44.7%) 218 (45.8%) 45 (9.5%) 0.948
  R1/R2 41 (44.1%) 44 (47.3%) 8 (8.6%)  
Neoadjuvant chemotherapy yes 161 (43.6%) 179 (48.5%) 29 (7.9%) 0.135
  no 93 (46.5%) 83 (41.5%) 24 (12.0%)  
Clinical response Responder 44 (41.9%) 52 (49.5%) 9 (8.6%) 0.885
  Nonresponder 117 (44.5%) 126 (47.9%) 20 (7.6%)  
TRG 1a,1b 44 (42.3%) 53 (51.0%) 7 (6.7%) 0.783
  2,3 116 (44.1%) 125 (47.5%) 22 (8.4%)  
  1. AEG = adenocarcinoma of the esophagogastric junction, GC = gastric cancer, TRG = tumor regression grade.